J Fraser Wright

List of Publications by Year
in descending order

29	7,375	279798 23	477307 29
papers	citations	h-index	g-index

30	30	30	9058
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Design of experiments as a decision tool for cell therapy manufacturing. Cytotherapy, 2022, 24, 590-596.	0.7	3
2	Quality Control Testing, Characterization and Critical Quality Attributes of Adenoâ€Associated Virus Vectors Used for Human Gene Therapy. Biotechnology Journal, 2021, 16, e2000022.	3.5	48
3	Challenges Posed by Immune Responses to AAV Vectors: Addressing Root Causes. Frontiers in Immunology, 2021, 12, 675897.	4.8	46
4	Development of Î²-globin gene correction in human hematopoietic stem cells as a potential durable treatment for sickle cell disease. Science Translational Medicine, 2021, 13, .	12.4	82
5	Timing of Intensive Immunosuppression Impacts Risk of Transgene Antibodies after AAV Gene Therapy in Nonhuman Primates. Molecular Therapy - Methods and Clinical Development, 2020, 17, 1129-1138.	4.1	34
6	Quantification of CpG Motifs in rAAV Genomes: Avoiding the Toll. Molecular Therapy, 2020, 28, 1756-1758.	8.2	29
7	Codon Modification and PAMPs in Clinical AAV Vectors: The Tortoise or the Hare?. Molecular Therapy, 2020, 28, 701-703.	8.2	48
8	Efficacy, Safety, and Durability of Voretigene Neparvovec-rzyl in RPE65 Mutationâ€“Associated Inherited Retinal Dystrophy. Ophthalmology, 2019, 126, 1273-1285.	5.2	239
9	Adeno-associated virus vectored immunoprophylaxis to prevent HIV in healthy adults: a phase 1 randomised controlled trial. Lancet HIV,the, 2019, 6, e230-e239.	4.7	84
10	Recombinant Adeno-Associated Virus Quality Control for Non-Clinical and Clinical Vectors: How an Unregulated Commercial Sector Can Compromise Development of New Gene Therapies. Human Gene Therapy, 2019, 30, 1447-1448.	2.7	3
11	Retinal AAV8-RS1 Gene Therapy for X-Linked Retinoschisis: Initial Findings from a Phase I/IIa Trial by Intravitreal Delivery. Molecular Therapy, 2018, 26, 2282-2294.	8.2	173
12	Hemophilia B Gene Therapy with a High-Specific-Activity Factor IX Variant. New England Journal of Medicine, 2017, 377, 2215-2227.	27.0	549
13	Safety and durability of effect of contralateral-eye administration of AAV2 gene therapy in patients with childhood-onset blindness caused by RPE65 mutations: a follow-on phase 1 trial. Lancet, The, 2016, 388, 661-672.	13.7	377
14	Effects of FVIII immunity on hepatocyte and hematopoietic stem cellâ€“directed gene therapy of murine hemophilia A. Molecular Therapy - Methods and Clinical Development, 2016, 3, 15056.	4.1	26
15	Safety, Biodistribution, and Efficacy of an AAV-5 Vector Encoding Human Interferon-Beta (ART-I02) Delivered via Intra-Articular Injection in Rhesus Monkeys with Collagen-Induced Arthritis. Human Gene Therapy Clinical Development, 2015, 26, 103-112.	3.1	17
16	Preclinical Potency and Biodistribution Studies of an AAV 5 Vector Expressing Human Interferon-Î² (ART-I02) for Local Treatment of Patients with Rheumatoid Arthritis. PLoS ONE, 2015, 10, e0130612.	2.5	24
17	Product-Related Impurities in Clinical-Grade Recombinant AAV Vectors: Characterization and Risk Assessment. Biomedicines, 2014, 2, 80-97.	3.2	115
18	AAV Empty Capsids: For Better or for Worse?. Molecular Therapy, 2014, 22, 1-2.	8.2	71

#	Article	IF	Citations
19	Bioengineered coagulation factor VIII enables long-term correction of murine hemophilia A following liver-directed adeno-associated viral vector delivery. Molecular Therapy - Methods and Clinical Development, 2014, 1, 14036.	4.1	35
20	Safety and tolerability of MRI-guided infusion of AAV2-hAADC into the mid-brain of nonhuman primate. Molecular Therapy - Methods and Clinical Development, 2014, 1, 14049.	4.1	24
21	Chimeric Antigen Receptorâ€"Modified T Cells for Acute Lymphoid Leukemia. New England Journal of Medicine, 2013, 368, 1509-1518.	27.0	3,021
22	Bioengineered Coagulation Factor VIII Enables Long-Term Correction Of Murine Hemophilia A Following Liver-Directed Adeno-Associated Viral Vector Delivery. Blood, 2013, 122, 4210-4210.	1.4	9
23	Vector Characterization Methods for Quality Control Testing of Recombinant Adeno-Associated Viruses. Methods in Molecular Biology, 2011, 737, 247-278.	0.9	23
24	Assessing the potential for AAV vector genotoxicity in a murine model. Blood, 2011, 117, 3311-3319.	1.4	196
25	New Adeno-Associated Virus Strategies to Support Momentum in the Clinic. Human Gene Therapy, 2011, 22, 519-521.	2.7	9
26	Manufacturing and Regulatory Strategies for Clinical AAV2-hRPE65. Current Gene Therapy, 2010, 10, 341-349.	2.0	33
27	Undetectable Transcription of cap in a Clinical AAV Vector: Implications for Preformed Capsid in Immune Responses. Molecular Therapy, 2009, 17, 144-152.	8.2	80
28	Transient Transfection Methods for Clinical Adeno-Associated Viral Vector Production. Human Gene Therapy, 2009, 20, 698-706.	2.7	112
29	Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nature Medicine, 2006, 12, 342-347.	30.7	1,865